Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Byetta Prescribers for Diabetes

Articles with lock require a subscription to GLG News | Request a free trial
Carlos DujovneFebruary 12, 2007
Drugs Effects on HDL Cholesterol Levels and Regression of Coronary Atherosclerosis
Analysis of: Effect of very high-intensity Statin therapy on regression of Coronary Atherosclerosis.Nissen S.E. etal | www.jama.com
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
1.This study's results are the first clinical confirmation of the benefits of a single drug to reverse coronary deposits of cholesterol in patients after just 2 years of treatment with Rosuvastatin (Crestor). 2. These results originated further clinical trials which will be presented at the forthcoming...
January 30, 2007
Missing Lessons in Torcetrapib Paradox
Analysis of: Torcetrapib tanks, but there is still a future in HDL cholesterol-raising therapies | www.theheart.org
Author: GLG Expert Contributor
The surrogate atherosclerosis end point studies with torcetrapib promise to give important, but likely complex clues regarding its paradoxical increase in CVD events and mortality. Some promising HDL-raising approaches still appear to be eluding pharmaceutical R&D.Niacin promises to be a big winner...
January 26, 2007
When will we stop underprescribing niacin for atheroprevention?
Analysis of: An Old Cholesterol Remedy Is New Again | www.nytimes.com
Author: GLG Expert Contributor
With the demise of the clinical development of Torcetrapib we are forced to reevaluate our views of HDL raising.We have had good HDL-raising drugs for many years, but they have gone underutilized and underappreciated.Many cardiologists (often supposed by others to be lipid experts) have never or rarely...

Previous Page : 1 2 3 4 5 6 7 8 9 1091 to 93 of 93

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747